447,796 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 447,796 shares of the company’s stock, valued at approximately $25,945,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SteelPeak Wealth LLC bought a new stake in Astrana Health during the 3rd quarter worth approximately $39,398,000. NorthCrest Asset Manangement LLC bought a new stake in Astrana Health during the 3rd quarter worth approximately $26,704,000. Principal Financial Group Inc. bought a new stake in Astrana Health during the 3rd quarter worth approximately $13,383,000. F M Investments LLC bought a new stake in Astrana Health during the 3rd quarter worth approximately $11,738,000. Finally, Diamond Hill Capital Management Inc. bought a new stake in Astrana Health during the 3rd quarter worth approximately $8,245,000. 52.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on ASTH shares. Truist Financial boosted their price objective on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, August 9th. BTIG Research boosted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen began coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price for the company. Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $65.17.

Astrana Health Stock Performance

ASTH stock opened at $43.42 on Thursday. The business has a 50 day moving average of $52.05 and a 200-day moving average of $48.05. Astrana Health, Inc. has a 12-month low of $32.32 and a 12-month high of $63.20. The firm has a market cap of $2.44 billion, a PE ratio of 33.40, a P/E/G ratio of 2.09 and a beta of 1.13. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The business had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. During the same period in the prior year, the company earned $0.47 earnings per share. As a group, sell-side analysts expect that Astrana Health, Inc. will post 1.16 earnings per share for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.